We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Shire Eyes Rare-Disease Market With Proposed Dyax Buy
Shire Eyes Rare-Disease Market With Proposed Dyax Buy
Continuing its string of proposed buyouts in the rare disease arena, Shire Pharmaceuticals is looking to snap up Massachusetts biotech Dyax in a deal worth up to $6.5 billion.